

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Ischemia/ reperfusion injury	Sirtuin 2 (SIRT2)	<p>Mouse studies suggest inhibiting SIRT2 could help treat ischemia/reperfusion injury. In a mouse model of ischemia/reperfusion injury, <i>Sirt2</i> knockout or an inhibitor of SIRT2 decreased necrosis and infarct size compared with no knockout or vehicle. Next steps include determining the time frame during which SIRT2 inhibitors have a therapeutic benefit in ischemia and testing whether modulating necrosis via SIRT2 inhibition could have benefit in other indications, such as neurodegenerative diseases. Indus Biotech Pte. Ltd.'s SIRT2 inhibitor INDUS815B is in preclinical development for Parkinson's disease (PD) and renal disease. The company also has the SIRT2 inhibitor INDUS815C in discovery for Huntington's disease (HD) and ophthalmic indications.</p> <p>SciBX 6(1); doi:10.1038/scibx.2013.12 Published online Jan. 10, 2013</p>	Patent application filed; available for licensing or partnering	<p>Narayan, N. <i>et al. Nature</i>; published online Nov. 28, 2012; doi:10.1038/nature11700</p> <p>Contact: Toren Finkel, National Institutes of Health, Bethesda, Md. e-mail: finkelt@nih.gov</p>